We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleAt What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness AnalysisAuthorsCohn, David E.; Kim, Kenneth H.; Resnick, Kimberly E.; O'Malley, David M.; Straughn, J. Michael JrPublicationJournal of Clinical Oncology, 2011, Vol 29, Issue 10, p1247ISSN0732-183xPublication typearticleDOI10.1200/jco.2010.32.1075